Clinical Trial

A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-02
Trial Details
NCT Number NCT07466550
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 60 participants
Start Date 2026-06-04
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-01